Skip to content

aTyr Pharma ATYR Operating lease liabilities

Operating lease liabilities at other companies

Vor Biopharma logo
Vor BiopharmaVOR
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Kura Oncology logo
Kura OncologyKURA

Other financials

Income statement

See full
Revenue-
Operating income-$11.4M+27.5%
Net income-$10.8M+27.5%
EPS (diluted)-$0.11+35.3%

Balance sheet

See full
Cash & equivalents$10.0M-3.4%
Total debt$12.3M-9.2%
Total equity$57.9M-22.8%
Total assets$79.7M-18.1%

Cash flow

See full
Operating cash flow-$12.5M+18.8%
CapEx$138.0K
Free cash flow-$12.7M+17.9%

Valuation

See full
Market cap$54.88M-88.2%
Enterprise value$57.17M
P/S288.8×

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-105.3%+50.6pp
Debt / equity0.2×0.0×
Current ratio5.8×-2.0×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is aTyr Pharma's operating lease liabilities?
aTyr Pharma (ATYR) reported operating lease liabilities of -$191K in Q1 2026.
How has aTyr Pharma's operating lease liabilities changed year-over-year?
aTyr Pharma's operating lease liabilities decreased by 17.9% year-over-year, from -$162K to -$191K.
What is the long-term trend for aTyr Pharma's operating lease liabilities?
Over 2 years (2021 to 2025), aTyr Pharma's operating lease liabilities has grown at a -9.1% compound annual growth rate (CAGR), from -$861K to -$711K.